113 related articles for article (PubMed ID: 17689077)
1. Identification of Sansalvamide a analog potent against pancreatic cancer cell lines.
Pan PS; McGuire KL; McAlpine SR
Bioorg Med Chem Lett; 2007 Sep; 17(18):5072-7. PubMed ID: 17689077
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines.
Otrubova K; Lushington G; Vander Velde D; McGuire KL; McAlpine SR
J Med Chem; 2008 Feb; 51(3):530-44. PubMed ID: 18186604
[TBL] [Abstract][Full Text] [Related]
3. Scaffold targeting drug-resistant colon cancers.
Otrubova K; McGuire KL; McAlpine SR
J Med Chem; 2007 May; 50(9):1999-2002. PubMed ID: 17411027
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29.
Styers TJ; Kekec A; Rodriguez R; Brown JD; Cajica J; Pan PS; Parry E; Carroll CL; Medina I; Corral R; Lapera S; Otrubova K; Pan CM; McGuire KL; McAlpine SR
Bioorg Med Chem; 2006 Aug; 14(16):5625-31. PubMed ID: 16697205
[TBL] [Abstract][Full Text] [Related]
5. N-methylsansalvamide a peptide analogues. Potent new antitumor agents.
Liu S; Gu W; Lo D; Ding XZ; Ujiki M; Adrian TE; Soff GA; Silverman RB
J Med Chem; 2005 May; 48(10):3630-8. PubMed ID: 15887970
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and cytotoxicity of novel sansalvamide A derivatives.
Carroll CL; Johnston JV; Kekec A; Brown JD; Parry E; Cajica J; Medina I; Cook KM; Corral R; Pan PS; McAlpine SR
Org Lett; 2005 Aug; 7(16):3481-4. PubMed ID: 16048322
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles.
Davis MR; Styers TJ; Rodriguez RA; Pan PS; Vasko RC; McAlpine SR
Org Lett; 2008 Jan; 10(2):177-80. PubMed ID: 18095697
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and novel structure-activity relationships of potent sansalvamide A derivatives.
Otrubova K; Styers TJ; Pan PS; Rodriguez R; McGuire KL; McAlpine SR
Chem Commun (Camb); 2006 Mar; (9):1033-4. PubMed ID: 16491200
[TBL] [Abstract][Full Text] [Related]
9. A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest.
Ujiki MB; Milam B; Ding XZ; Roginsky AB; Salabat MR; Talamonti MS; Bell RH; Gu W; Silverman RB; Adrian TE
Biochem Biophys Res Commun; 2006 Feb; 340(4):1224-8. PubMed ID: 16414351
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor activity of cyclodepsipeptide zygosporamide and its analogues.
Wang Y; Zhang F; Zhang Y; Liu JO; Ma D
Bioorg Med Chem Lett; 2008 Aug; 18(15):4385-7. PubMed ID: 18606540
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of second-generation sansalvamide A derivatives: novel templates as potential antitumor agents.
Rodriguez RA; Pan PS; Pan CM; Ravula S; Lapera S; Singh EK; Styers TJ; Brown JD; Cajica J; Parry E; Otrubova K; McAlpine SR
J Org Chem; 2007 Mar; 72(6):1980-2002. PubMed ID: 17315929
[TBL] [Abstract][Full Text] [Related]
12. Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents.
Di Maro S; Pong RC; Hsieh JT; Ahn JM
J Med Chem; 2008 Nov; 51(21):6639-41. PubMed ID: 18839938
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of kahalalide F synthetic analogues.
Jiménez JC; López-Macià A; Gracia C; Varón S; Carrascal M; Caba JM; Royo M; Francesch AM; Cuevas C; Giralt E; Albericio F
J Med Chem; 2008 Aug; 51(16):4920-31. PubMed ID: 18672864
[TBL] [Abstract][Full Text] [Related]
14. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.
Zask A; Kaplan J; Musto S; Loganzo F
J Am Chem Soc; 2005 Dec; 127(50):17667-71. PubMed ID: 16351096
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic and Antihaptotactic beauvericin analogues from precursor-directed biosynthesis with the insect pathogen Beauveria bassiana ATCC 7159.
Xu Y; Zhan J; Wijeratne EM; Burns AM; Gunatilaka AA; Molnár I
J Nat Prod; 2007 Sep; 70(9):1467-71. PubMed ID: 17803266
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines.
Pan PS; Vasko RC; Lapera SA; Johnson VA; Sellers RP; Lin CC; Pan CM; Davis MR; Ardi VC; McAlpine SR
Bioorg Med Chem; 2009 Aug; 17(16):5806-25. PubMed ID: 19643615
[TBL] [Abstract][Full Text] [Related]
17. Cytoskeleton alterations induced by Geodia corticostylifera depsipeptides in breast cancer cells.
Rangel M; Prado MP; Konno K; Naoki H; Freitas JC; Machado-Santelli GM
Peptides; 2006 Sep; 27(9):2047-57. PubMed ID: 16843570
[TBL] [Abstract][Full Text] [Related]
18. N-Triethylene glycol (N-TEG) as a surrogate for the N-methyl group: application to Sansalvamide A peptide analogs.
Fernández-Llamazares AI; García J; Soto-Cerrato V; Pérez-Tomás R; Spengler J; Albericio F
Chem Commun (Camb); 2013 Jul; 49(57):6430-2. PubMed ID: 23752923
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationship of cytotoxic marine cyclodepsipeptide IB-01212 analogues.
Cruz LJ; Francesch A; Cuevas C; Albericio F
ChemMedChem; 2007 Jul; 2(7):1076-84. PubMed ID: 17514692
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and cytotoxicity testing of novel 2-(3-substituted-6-chloro-1,1-dioxo-1,4,2-benzodithiazin-7-yl)-3-phenyl-4(3H)-quinazolinones.
Pomarnacka E; Maruszak M; Langowska K; Reszka P; Bednarski PJ
Arch Pharm (Weinheim); 2008 Aug; 341(8):485-90. PubMed ID: 18618486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
